Atrion (NASDAQ:ATRI) and SANUWAVE Health (OTCMKTS:SNWV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.
Institutional and Insider Ownership
63.8% of Atrion shares are owned by institutional investors. Comparatively, 0.4% of SANUWAVE Health shares are owned by institutional investors. 22.5% of Atrion shares are owned by insiders. Comparatively, 23.4% of SANUWAVE Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Atrion has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, SANUWAVE Health has a beta of -1.62, suggesting that its share price is 262% less volatile than the S&P 500.
Atrion pays an annual dividend of $5.40 per share and has a dividend yield of 0.7%. SANUWAVE Health does not pay a dividend. Atrion has increased its dividend for 16 consecutive years.
This is a summary of recent ratings for Atrion and SANUWAVE Health, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation and Earnings
This table compares Atrion and SANUWAVE Health’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Atrion||$146.60 million||9.95||$36.59 million||N/A||N/A|
|SANUWAVE Health||$740,000.00||42.70||-$5.53 million||($0.04)||-5.08|
Atrion has higher revenue and earnings than SANUWAVE Health.
This table compares Atrion and SANUWAVE Health’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Atrion beats SANUWAVE Health on 10 of the 12 factors compared between the two stocks.
Atrion Company Profile
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise MPS2 myocardial protection system that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products that are used in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measures the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers, as well as other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
SANUWAVE Health Company Profile
SANUWAVE Health, Inc., a shock wave technology company, focuses on the development and commercialization of noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications worldwide. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead product candidate is the dermaPACE device, which has completed its initial Phase III, IDE clinical trial for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. It markets and sells its devices and accessories. SANUWAVE Health, Inc. was founded in 2005 and is headquartered in Suwanee, Georgia.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.